{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:12:23Z","timestamp":1791000743561,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10067-016-3485-5","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T06:36:36Z","timestamp":1480660596000},"page":"241-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis"],"prefix":"10.1007","volume":"36","author":[{"name":"on behalf of the British Society for Rheumatology Biologics Register","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Kearsley-Fleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath D.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah P.M.","family":"Symmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"3485_CR1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EHS Choy","year":"2001","unstructured":"Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916","journal-title":"N Engl J Med"},{"key":"3485_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509","journal-title":"Ann Rheum Dis"},{"key":"3485_CR3","first-page":"1426","volume":"30","author":"N Nishimoto","year":"2003","unstructured":"Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Tagaki N, Kishimoto T (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with. J Rheumatol 30:1426\u20131435","journal-title":"J Rheumatol"},{"key":"3485_CR4","unstructured":"NICE (2010) Tocilizumab for the treatment of rheumatoid arthritis. NICE Technol. Apprais. Guid. 198"},{"key":"3485_CR5","unstructured":"NICE (2012) Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). In: NICE Technol. Apprais. Guid. 247. https:\/\/www.nice.org.uk\/guidance\/ta247"},{"key":"3485_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541\u20131550. doi: 10.1016\/S0140-6736(13)60250-0","journal-title":"Lancet"},{"key":"3485_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2879-0","author":"M Backhaus","year":"2015","unstructured":"Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske A-E, Hellmann P, Gaubitz M (2015) Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol. doi: 10.1007\/s10067-015-2879-0","journal-title":"Clin Rheumatol"},{"key":"3485_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s10067-013-2281-8","volume":"32","author":"J Kaufmann","year":"2013","unstructured":"Kaufmann J, Feist E, Roske AE, Schmidt W a (2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 32:1347\u20131355. doi: 10.1007\/s10067-013-2281-8","journal-title":"Clin Rheumatol"},{"key":"3485_CR9","doi-asserted-by":"crossref","unstructured":"Rom\u00e3o VC, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, Costa JA, Bernardes M, Pimentel-Santos FM, Barcelos F, Costa L, Ant\u00f3nio J, Gomes M, Alberto J, Branco JC, Canas J, Ant\u00f3nio J, Fonseca JE, Canh\u00e3o H (2015) Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the Rheumatic Diseases Portuguese Register, Reuma. pt. 2015","DOI":"10.1155\/2015\/279890"},{"key":"3485_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3899\/jrheum.130466","volume":"41","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15\u201323. doi: 10.3899\/jrheum.130466","journal-title":"J Rheumatol"},{"key":"3485_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00296-015-3237-x","volume":"35","author":"A Balsa","year":"2015","unstructured":"Balsa A, Tovar Beltran JV, Caliz Caliz R, Mateo Bernardo I, Garcia-Vicun AR, Rodriguez-Gomez M, Belmonte Serrano MA, Marras C, Loza Cortina E, Perez-Pampin E, Vila V (2015) Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int 35:1525\u20131534. doi: 10.1007\/s00296-015-3237-x","journal-title":"Rheumatol Int"},{"key":"3485_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2015.07.001","volume":"45","author":"J Narv\u00e1ez","year":"2015","unstructured":"Narv\u00e1ez J, Magallares B, D\u00edaz Torn\u00e9 C, Hern\u00e1ndez MV, Reina D, Corominas H, Sanmart\u00ed R, LLobet JM, Rodriguez de la Serna A, Nolla JM (2015) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 45:1\u20135. doi: 10.1016\/j.semarthrit.2015.07.001","journal-title":"Semin Arthritis Rheum"},{"key":"3485_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TWJ (2014) Clinical, radiographic and immunogenic effects after 1\u00a0year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:803\u2013809. doi: 10.1136\/annrheumdis-2013-204761","journal-title":"Ann Rheum Dis"},{"key":"3485_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","volume":"74","author":"TWJ Huizinga","year":"2015","unstructured":"Huizinga TWJ, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35\u201343. doi: 10.1136\/annrheumdis-2014-205752","journal-title":"Ann Rheum Dis"},{"key":"3485_CR15","doi-asserted-by":"crossref","unstructured":"Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study ). 1\u20137. doi: 10.1136\/annrheumdis-2015-208426","DOI":"10.1136\/annrheumdis-2015-208426"},{"key":"3485_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/rheumatology\/keu302","volume":"54","author":"T Kojima","year":"2015","unstructured":"Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N (2015) Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 54:113\u2013120. doi: 10.1093\/rheumatology\/keu302","journal-title":"Rheumatology (Oxford)"},{"key":"3485_CR17","doi-asserted-by":"publisher","first-page":"207760","DOI":"10.1136\/annrheumdis-2015-207760","volume":"2015","author":"C Gabay","year":"2015","unstructured":"Gabay C, Riek M, Hetland ML, Hauge E-M, Pavelka K, Tom\u0161i\u010d M, Canhao H, Chatzdionysiou K, Lukina G, Nordstr\u00f6m DC, Lie E, Ancuta I, Hern\u00e1ndez MV, van Riel PLMC, van Vollenhoven R, Kvien TK (2015) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis annrheumdis 2015:207760. doi: 10.1136\/annrheumdis-2015-207760","journal-title":"Ann Rheum Dis annrheumdis"},{"key":"3485_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/14397595.2014.897793","volume":"25","author":"K Izumi","year":"2015","unstructured":"Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T (2015) Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and\/or TNF inhibitors: a single-center retrospective. Mod Rheumatol 25:31\u201337. doi: 10.3109\/14397595.2014.897793","journal-title":"Mod Rheumatol"},{"key":"3485_CR19","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF (2005) The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23:S14\u2013S18","journal-title":"Clin Exp Rheumatol"},{"key":"3485_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"a M Gestel van","year":"1996","unstructured":"van Gestel a M, Prevoo ML, van\u2019t Hof M a, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 39:34\u201340. doi: 10.1002\/art.1780390105","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"3485_CR21","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1136\/ard.59.suppl_1.i28","volume":"59","author":"PL Riel van","year":"2000","unstructured":"van Riel PL, van Gestel a M (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28\u2013i31. doi: 10.1136\/ard.59.suppl_1.i28","journal-title":"Ann Rheum Dis"},{"key":"3485_CR22","first-page":"400","volume":"28","author":"DE Beaton","year":"2001","unstructured":"Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, Strand V, Shea B (2001) Looking for important change\/differences in studies of responsiveness. J Rheumatol 28:400\u2013405","journal-title":"J Rheumatol"},{"key":"3485_CR23","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1002\/art.11407","volume":"49","author":"J Fransen","year":"2003","unstructured":"Fransen J, Stucki G, van Riel PLCM (2003) Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 49:S214\u2013S224. doi: 10.1002\/art.11407","journal-title":"Arthritis Rheum"},{"key":"3485_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hernan MA (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656\u2013664. doi: 10.1093\/aje\/kwn164","journal-title":"Am J Epidemiol"},{"key":"3485_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.amjmed.2010.11.028","volume":"124","author":"M Ramos-Casals","year":"2011","unstructured":"Ramos-Casals M, Perez-Alvarez R, Perez-De-Lis M, Xaubet A, Bosch X (2011) Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 124:386\u2013394. doi: 10.1016\/j.amjmed.2010.11.028","journal-title":"Am J Med"},{"key":"3485_CR26","doi-asserted-by":"publisher","unstructured":"Mercer LK, Lunt M, Low ALS, Dixon WG, Watson KD, Symmons DPM, Hyrich KL (2014) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis:1\u20137. doi: 10.1136\/annrheumdis-2013-204851","DOI":"10.1136\/annrheumdis-2013-204851"},{"key":"3485_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semarthrit.2009.09.001","volume":"40","author":"AA Khasnis","year":"2010","unstructured":"Khasnis AA, Calabrese LH (2010) Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 40:147\u2013163. doi: 10.1016\/j.semarthrit.2009.09.001","journal-title":"Semin Arthritis Rheum"},{"key":"3485_CR28","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285. doi: 10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"key":"3485_CR29","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","volume":"49","author":"T Ding","year":"2010","unstructured":"Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C (2010) BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 49:2217\u20132219. doi: 10.1093\/rheumatology\/keq249a","journal-title":"Rheumatology (Oxford)"},{"key":"3485_CR30","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141. doi: 10.1186\/ar3455","journal-title":"Arthritis Res Ther"},{"key":"3485_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","volume":"36","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T (2016) Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case???Control study. Rheumatol Int 36:881\u2013889. doi: 10.1007\/s00296-016-3478-3","journal-title":"Rheumatol Int"},{"key":"3485_CR32","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/ker295","volume":"50","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, Deshpande G a, Matsui K, Kishimoto M (2011) An observational study of tocilizumab and TNF-\u03b1 inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford) 50:2093\u20132099. doi: 10.1093\/rheumatology\/ker295","journal-title":"Rheumatology (Oxford)"},{"key":"3485_CR33","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/art.21830","volume":"54","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Symmons DPM, Watson KD, Silman AJ (2006) Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:1786\u20131794. doi: 10.1002\/art.21830","journal-title":"Arthritis Rheum"},{"key":"3485_CR34","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.39169","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A (2015) Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 67:2011\u20132019. doi: 10.1002\/art.39169","journal-title":"Arthritis Rheumatol"},{"key":"3485_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/art.27740","volume":"63","author":"JS Smolen","year":"2011","unstructured":"Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63:43\u201352. doi: 10.1002\/art.27740","journal-title":"Arthritis Rheum"},{"key":"3485_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10165-010-0402-7","volume":"21","author":"S-Y Kawashiri","year":"2011","unstructured":"Kawashiri S-Y, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K (2011) Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol 21:365\u2013369. doi: 10.1007\/s10165-010-0402-7","journal-title":"Mod Rheumatol"},{"key":"3485_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10165-009-0203-z","volume":"19","author":"K Funahashi","year":"2009","unstructured":"Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T (2009) Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 19:507\u2013512. doi: 10.1007\/s10165-009-0203-z","journal-title":"Mod Rheumatol"},{"key":"3485_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66:407\u2013409. doi: 10.1136\/ard.2006.054205","journal-title":"Ann Rheum Dis"},{"key":"3485_CR39","doi-asserted-by":"publisher","unstructured":"Akiyama M, Kaneko Y, Kondo H, Takeuchi T (2016) Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol:1\u20136. doi: 10.1007\/s10067-016-3227-8","DOI":"10.1007\/s10067-016-3227-8"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3485-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:07:46Z","timestamp":1498352866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["3485"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3485-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}